Skip to main content

Zymeworks Inc.

corporate_fare Company Profile

Zymeworks Inc.

ZYME·NASDAQ·Life Sciences·CIK 0001937653

Zymeworks is a global biotechnology company that manages a portfolio of licensed healthcare assets and develops new, multifunctional biotherapeutics. These biotherapeutics aim to improve treatment for difficult conditions such as cancer, inflammation, and autoimmune disease. The company's strategy focuses on increasing stockholder value through royalty growth, strategic acquisitions, and internal innovation. This is supported by disciplined capital allocation and a stronger financial foundation from expected milestone payments and royalties from existing commercial partners. Zymeworks discovers or acquires and develops a diversified portfolio of preclinical or clinical healthcare assets. It also evaluates strategic partnership opportunities to transfer certain costs and risks related to clinical development and/or commercialization to partners, securing the right to receive potential future royalty and milestone revenues. The company uses its expertise in protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics for significant unmet medical needs, especially in hard-to-treat diseases. Its proprietary structure-guided molecular modeling, combined with internal antibody discovery and generation technologies, supports a fully integrated drug development engine. Zymeworks' pipeline of multifunctional therapeutics is supported by its multispecific antibody therapeutics ("MSATs") and antibody-drug conjugates ("ADCs") technology platforms, which enable the development of novel therapeutics in cancer, inflammation, and autoimmune disease and create opportunities for new partnerships. Partnerships and collaborations are a key part of its strategy, serving as a potential source of funding for ongoing research and development and reducing reliance on internal capital for later-stage clinical development of partnered assets.

Zymeworks Inc. (NASDAQ:ZYME) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ZYME at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ZYME spans 10-Q, 8-K.

Recent high-impact activity:

  • $200M Buyback Authorized, Doubling Down After $125M Program Wrapped
  • Zymeworks 10-Q Details $173.7M Q3 Profit, $560M Theravance Deal Accounting
  • Zymeworks Raises 2026 Revenue Guidance to $337M-$351M Following $250M Jazz Milestone
  • Zymeworks Posts $2.28 Per-Share Profit in Third Quarter
  • ZW191 Hits 64.5% Response Rate at 6.4 mg/kg With Half the Severe Toxicity

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$105.97M
Net Income
-$81.13M
Diluted EPS
-$1.08
Op. Cash Flow
-$33.01M
Free Cash Flow
-$34.53M
Operating Income
-$92.55M
Cash & Equivalents
$41.16M
Debt / Equity
0.00×
Net Margin
-76.6%
Shares Outstanding
74.64M sh
Source: 10-K · filed 2026-03-02 · accession 0001937653-26-000015

Short Interest & Short Volume

4.25 days to cover

FINRA reported short interest of 5,914,601 shares in ZYME as of the October 30, 2026 settlement, a 6.0% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 68.2% of ZYME volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,914,601 shares as of October 30, 2026
Change vs prior period▲ 6.0%
Days to cover4.25 at avg daily volume of 1,392,562
Daily short volume (FINRA facilities)68.2% of 196,143 shares on November 20, 2026
5-day average short volume70.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with Z →
$26.14
52-week range · as of 2026-11-09 $16 – $31.49
Market cap
$1.81B
Volume
738.8K (0.6× avg)
3-mo avg 1.3M
Live data · 2026-11-21 07:57 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZYME - Latest Insights

ZYME
Nov 16, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $26.30
Real-time Price: $26.14 info
Change: -$0.160 (-0.61%) info
Market Cap: $1.81B info
ZYME
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $26.14 info
Change: -$4.67 (-15%) info
Market Cap: $1.81B info
ZYME
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $26.14 info
Change: -$4.67 (-15%) info
Market Cap: $1.81B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $26.14 info
Change: -$4.67 (-15%) info
Market Cap: $1.81B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $26.14 info
Change: -$2.41 (-8%) info
Market Cap: $1.81B info
ZYME
Oct 23, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.99
Real-time Price: $26.14 info
Change: -$2.85 (-10%) info
Market Cap: $1.81B info
ZYME
Sep 28, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $26.52
Real-time Price: $26.14 info
Change: -$0.380 (-1%) info
Market Cap: $1.81B info
ZYME
Sep 23, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.32
Real-time Price: $26.14 info
Change: -$1.18 (-4%) info
Market Cap: $1.81B info
ZYME
Aug 25, 2026, 10:54 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $27.91
Real-time Price: $26.14 info
Change: -$1.77 (-6%) info
Market Cap: $1.81B info
ZYME
Aug 25, 2026, 10:23 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $29.55
Real-time Price: $26.14 info
Change: -$3.41 (-12%) info
Market Cap: $1.81B info
ZYME
Aug 06, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.13
Real-time Price: $26.14 info
Change: +$3.01 (+13%) info
Market Cap: $1.81B info
ZYME
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.13
Real-time Price: $26.14 info
Change: +$3.01 (+13%) info
Market Cap: $1.81B info
ZYME
Jun 29, 2026, 7:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $23.82
Real-time Price: $26.14 info
Change: +$2.32 (+10%) info
Market Cap: $1.81B info
ZYME
Jun 29, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $23.82
Real-time Price: $26.14 info
Change: +$2.32 (+10%) info
Market Cap: $1.81B info
ZYME
Jun 29, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $23.75
Real-time Price: $26.14 info
Change: +$2.39 (+10%) info
Market Cap: $1.81B info
ZYME
May 14, 2026, 4:29 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.80
Real-time Price: $26.14 info
Change: +$1.34 (+5%) info
Market Cap: $1.81B info
ZYME
May 14, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $24.54
Real-time Price: $26.14 info
Change: +$1.60 (+7%) info
Market Cap: $1.81B info
ZYME
May 07, 2026, 4:36 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $26.78
Real-time Price: $26.14 info
Change: -$0.640 (-2%) info
Market Cap: $1.81B info
ZYME
May 07, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.78
Real-time Price: $26.14 info
Change: -$0.640 (-2%) info
Market Cap: $1.81B info
ZYME
May 07, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $26.78
Real-time Price: $26.14 info
Change: -$0.640 (-2%) info
Market Cap: $1.81B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets